J&J Raises Its Earnings Forecast Because To High Demand For Top-Seller Stelara
In its first earnings report after spinning off its consumer health division, Johnson & Johnson increased its 2023 profit projection. The company’s fortunes are now more tightly related to sales of blockbusters like its arthritis medicine Stelara. The company’s shares increased by around 2% in Tuesday’s premarket trade. Investor attention is centred on J&J’s ability…









